Tricuspid valve papillary fibroelastoma in an adult patient: a case report and review of literature Authors: Zhenchun Ji, Changhui Yu, Kadeerjiang Musha, Liangqiang Lin, Baihetiya Saimi, Abudusalamu Abudurexiti, Haoyue Huang, Zhenya Shen Published: 2025 ABSTRACT BackgroundTricuspid valve papillary fibroelastoma is a rare, benign primary cardiac tumor located on the tricuspid valve, with a potential risk of embolism. Here, we report a case of tricuspid valve papillary fibroelastoma successfully treated with surgical resection. The patient remained recurrence-free after a one-year follow-up.Case presentationA 51-year-old female patient was admitted with a three-year history of chest tightness and shortness of breath. Transthoracic echocardiography revealed a 10 × 9 mm mass at the root of the right atrial surface of the anterior tricuspid valve leaflet, exhibiting movement in sync with valve opening and closing. The patient underwent surgical resection, and histopathological examination confirmed the diagnosis of papillary fibroelastoma.ConclusionsTricuspid valve papillary fibroelastoma is still a rare benign cardiac tumor. Echocardiography serves as a reliable diagnostic tool. By reviewing the literature, we suggest that for tricuspid valve PFE with right-sided embolism and with a diameter greater than 5 mm, early surgical resection should be considered to prevent serious complications such as embolization. Introduction Papillary fibroelastoma (PFE) is a slow-growing, benign cardiac tumor with an associated risk of embolism [1, 4]. Its etiology remains unknown, and it accounts for 8–16% of primary cardiac tumors [5, 7]. PFE predominantly affects cardiac valves, with the aortic valve being the most common site, while involvement of the tricuspid valve is rare [8]. Transthoracic and transesophageal echocardiography are the primary diagnostic modalities used to distinguish PFE from valvular vegetations. Surgical resection remains the standard treatment, aiming to preserve valve integrity and function. Given the risk of embolization, surgery is typically recommended unless contraindicated [9]. But there is no standardized treatment protocol for tricuspid valve PFE, the surgical indications is still controversial. Here, we present a case of tricuspid valve PFE and provide a comprehensive review of the literature to clarify the treatment options for this disease. Case presentation A 51-year-old female patient was admitted with a three-year history of exertional chest tightness and dyspnea. She denied experiencing chest pain, palpitations, or fever. Her medical history included cranial cavernous angioma resection in 2019, and there was no family history of cardiac tumor. On physical examination, her temperature (T) was 36.7 °C, blood pressure (BP) was 118/79 mmHg, and heart rate was 71 beats per minute. Cardiac auscultation revealed no pathological murmurs. Electrocardiography showed sinus rhythm without ST-segment changes. Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) identified a 10 × 9 mm mass at the root of the right atrial surface of the anterior tricuspid valve leaflet (Figure 1A). The mass exhibited significant mobility without restricting leaflet opening or causing tricuspid valve mild insufficiency (Figure 1B). The pulmonary artery systolic pressure and mean pulmonary artery pressure estimated by echocardiography were 30 mmHg and 20 mmHg respectively. Coronary angiography revealed 40% stenosis in the proximal anterior descending artery. Pulmonary artery computed tomography angiography ruled out pulmonary embolism. Routine blood showed normal leukocyte levels, erythrocyte sedimentation rate and C-reactive protein levels. The tricuspid valve mass was suspected to be a papillary fibroelastoma (PFE). Given its potential embolic risk, either from the mass itself or an associated thrombus, the patient underwent complete tumor excision easily on a beating heart under cardiopulmonary bypass, without cardioplegic arrest. The surgery was performed via median sternotomy. The ascending aorta, superior vena cava and inferior vena cava were cannulated to establish extracorporeal circulation. The cardio pulmonary bypass time was 35 min. Upon opening the right atrium, the tumor was found near the anterior tricuspid valve leaflet. It had a short stalk originating from the root of the anterior leaflet, which was easily fragmentable, with a mass diameter of approximately 10 mm and a pedicle measuring about 1 mm (Figures 1C and D). The tricuspid valve remained intact, with no evidence of closure insufficiency; therefore, tricuspid valvuloplasty was not performed. Postoperative histopathological examination confirmed the diagnosis of PFE (Figure 1E). The patient recovered well and was discharged on postoperative day 5. Follow-up echocardiography over the course of one year showed no tumor recurrence.Fig. 1(A) Transthoracic echocardiography showed a mass at the root of the right atrial surface of the tricuspid valve anterior leaflet. The arrow indicates the mass,10mmX9mm large. (B) Ultrasound Color Doppler suggests mild tricuspid regurgitation. (C) Intraoperative photograph showing the tumor attached to the root of the right atrial surface of the anterior tricuspid valve leaflet. (D) Gross view of the tumor showing a gelatinous mass, 10mmX9mm large. The mass shows a villous structure in water, with an anemone-like appearance, the arrow indicates the brownish-white stalk. (E) Histopathological examination of the tumor showing an avascular central core of hyalinized connective tissue with papillary fronds, covered by a single layer of endocardial cells (A) Transthoracic echocardiography showed a mass at the root of the right atrial surface of the tricuspid valve anterior leaflet. The arrow indicates the mass,10mmX9mm large. (B) Ultrasound Color Doppler suggests mild tricuspid regurgitation. (C) Intraoperative photograph showing the tumor attached to the root of the right atrial surface of the anterior tricuspid valve leaflet. (D) Gross view of the tumor showing a gelatinous mass, 10mmX9mm large. The mass shows a villous structure in water, with an anemone-like appearance, the arrow indicates the brownish-white stalk. (E) Histopathological examination of the tumor showing an avascular central core of hyalinized connective tissue with papillary fronds, covered by a single layer of endocardial cells Discussion Primary cardiac tumors are rare, with PFEs being among the common types [40]. Approximately 6–15% of the PFEs occur on the tricuspid valve [19]. Most tricuspid valve PFEs are asymptomatic and are often incidentally detected during routine examinations. However, in some cases, they can cause severe symptoms of pulmonary embolism [26], presenting as sudden dyspnea and chest discomfort. Patients with tricuspid valve obstruction may experience lower limb edema and hepatic congestion. It is particularly important, as PFE embolism may be caused by small fragments of tumor or little thrombi and not necessarily by the entire tumor migration. There is an important difference between left- and right-sided localization of PFE. Systemic embolization (particularly to the central nervous system or coronary arteries) may be more dangerous compared to small pulmonary embolism, which may be asymptomatic, not causing significant complications. Additionally, PFEs can lead to arrhythmias, resulting in palpitations, dizziness, or syncope [41]. The case we reported primarily presented with nonspecific dyspnea, but no evidence of pulmonary embolism and tricuspid regurgitation was found. So the patient’s clinical symptoms may not be related to the tricuspid valve PFE and may be related to the coronary stenosis. The size of cardiac PFEs ranges from 2 to 70 mm, with most measuring around 10 mm in diameter [42], which aligns with the findings in our case. Transthoracic echocardiography is routinely used for diagnosing tricuspid valve PFE. However, its sensitivity and specificity are low for tumors smaller than 2 mm. In such patients, transesophageal echocardiography should be performed, as it provides superior resolution, clearer visualization of the tumor-valve relationship, and greater utility in differential diagnosis [43]. Tricuspid valve PFE typically appears on echocardiography as a well-defined, small, mobile, pedicled mass attached to the tricuspid valve or tendon cords, with the potential to prolapse into the cardiac chambers during the cardiac cycle. Another characteristic feature is a “speckled or stippled” appearance due to peripheral echolucencies at the blood-tumor interface [41]. Cardiac computed tomography (CCT) and cardiac magnetic resonance (CMR) serve as secondary imaging modalities for diagnosing tricuspid valve PFE [25]. While CCT has limited resolution, CMR offers better tissue characterization and can aid in diagnosis [44]. Differentiation from thrombi and valvular vegetations is essential. Thrombi rarely form on valves, tend to be relatively fixed, and exhibit minimal mobility. In our case, the patient had no risk factors for infectious endocarditis, a normal leukocyte count, no fever, and negative blood cultures, making infective endocarditis unlikely. Differentiation from myxoma is also crucial, as myxomas are typically larger, cause significant obstruction, impair valve function, and have a distinct echocardiographic appearance [45]. Given these factors, we did not consider myxoma in this case. Literature search in databases such as PubMed, Embase was conducted between 1983 and 2025, the search term was “papillary fibroelastoma” in combination with “tricuspid valve”. Including our case, a total of 69 reported cases of tricuspid valve PFE was identified. Of these, 33 cases were published in the last five years, accounting for nearly half of all reported cases. However, detailed data were unavailable for 37 cases (n = 10 [4,9], n = 6 [46], n = 5 [47], n = 2 [48], n = 1 [49], n = 2 [20], n = 1 [50]). The remaining 32 cases are summarized in Table 1. The ranged in age from 1 to 81 years old, with a median age of 63 years (interquartile range: 71.75–50.25). The male-to-female ratio was 17:15. Clinically, 10 cases were asymptomatic and detected incidentally, while 15 cases presented with dyspnea, seven with chest pain, three with fever, two with syncope, one with dizziness, and one with palpitations. These symptoms were nonspecific and not directly attributed to tricuspid valve PFE.Table 1Clinical Presentations of the Reported Cases and the Current CaseReferencesAge(years)SexClinical findingSize(mm) orM(Q1-Q3)SurgeryComorbidityDays in hospitalFollow-up(months)Ali Ahmad et al. [10], 202443MNone6 × 5TVP, MV repair, PVI, app ligation,ResectionAF3NR in 1Kamel I et al. [11], 202460MSyncope16 × 17ResectionHTN; head injuryNoneNAKu L et al. [12], 202431MNone14 × 12ResectionNone7NAChen D et al. [5], 202455MChest pain19 × 14ResectionNoneNoneNABashir H et al. [13], 202481MChest pain;afebrile13 × 12CABG, AVR;ResectionCHD, HTNNoneNAWang Y et al. [14], 202373MNone8.4 × 6TVPResectionNone8NR in 15Actis Dato GM et al. [15], 202369FNone20 × 10ResectionNone6NAPhan TQ et al.,[16] 202317FDyspnea8.7 × 9.6ResectionNone3NR in 6Zhang RS et al.,[17] 202360FNone15 × 11Resection by cardiac catheterizationDM;HTN; TR, ischemic strokeNANAFang L et al. [18], 202251MDyspneaNATVR,Resection,TRNANARana Y et al.,[19] 202166MDyspnea17 × 13Resection,PFO closureHIV, DM, HTN, hyperlipidemia3NRKashiwagi Y et al.,[20] 202162FPalpitation23 × 17ResectionRBBB, PENANAKavalerchyk V et al. [21], 201874MChest pain,dyspnea10 × 8Conservative treatmentCHD-No change in 36Artunduaga M et al. [22], 20171FNone15 × 15TVP;ResectionNone6NARohani A et al. [23], 201764fChest pain9 × 6ResectionTRNANR in 6Gollol-Raju NSet al. [24], 201671MDyspnea11 × 9.4Resection by cardiac catheterizationNon-ischemic cardiomyopathy; HTN;NANR in 1Li W et al. [25], 201675MNone20 × 15TVP,ResectionCHD, HTN, ischemic stroke7NR in 6Choi KB t al [26], 201672MDyspnea,afebrile13 × 16TVP;ResectionNoneNANRShah RA et al. [27], 201565MDyspnea10 × 10 × 5ResectionTR, PE, PHNANR in 12Srivatsa SV et al.,[28] 201361FDyspnea13 × 9 × 11ResectionTR, PHNANR in 2Karimi M et al. [29], 20138MChest paindyspnea25 × 15TVR;ResectionTR, PENANRKarapanagiotidis GT et al. [30], 201281FDyspnea,Dizzy spells20 × 25TVP;ResectionTR7NR in 3Haron H et al. [31], 201268MAfebrile10 × 10MVR; TVP;ResectionDM;HTN; MI; TR6NR in 12Massarenti L et al. [32], 200950FNone16 × 17TVP;ResectionNone7NABoodhwani M et al. [33], 200738MDyspnea15 × 20TVP;ResectionNANANAMastroroberto P et al. [34], 200653MChest pain;dyspnea20 × 30CABG;ResectionCHD, PENANAGeorghiou GP al. [35], 200367FDyspnea25 × 16ResectionNoneNANR in 4Nishimura Y et al. [36], 199842FNone40 × 35TVP;ResectionTRNANR in 12Neerukonda SK et al. [37], 199175FDyspnea1.5 × 2.0/33 × 2.0 × 18TVP;ResectionPENANAWolfe JT 3rd et al. [38], 199175FNone27 × 27CABG;ResectionCerebral ischemic15Recurrence in 0.5Frumin H et al. [39], 198364FChest painsyncope15 × 15CABG;ResectionCHDNANACurrent study53FDyspnea10 × 9ResectionNone5NR in 12M,male;F,female;TVP,tricuspid valvuloplasty;MV, mitral valve;PVI, pulmonary vein isolation;AF,atrial fibrillation;NR, non-tumor recurrence; NA,not available; HTN, hypertension;CABG, coronary artery bypass grafting; CHD,coronary artery disease;AVR, aortic valve replacement;DM, diabetes mellitus;TR,tricuspid regurgitation;TVR,tricuspid valve replacement;HIV,human immunodeficiency virus;PFO,patent foramen ovale;PE,pulmonary embolism;RBBB,right bundle-branch block;PH:pulmonary arterial hypertension;MI,mitral insufficiency;MVR, mitral valve replacement Table 1Clinical Presentations of the Reported Cases and the Current CaseReferencesAge(years)SexClinical findingSize(mm) orM(Q1-Q3)SurgeryComorbidityDays in hospitalFollow-up(months)Ali Ahmad et al. [10], 202443MNone6 × 5TVP, MV repair, PVI, app ligation,ResectionAF3NR in 1Kamel I et al. [11], 202460MSyncope16 × 17ResectionHTN; head injuryNoneNAKu L et al. [12], 202431MNone14 × 12ResectionNone7NAChen D et al. [5], 202455MChest pain19 × 14ResectionNoneNoneNABashir H et al. [13], 202481MChest pain;afebrile13 × 12CABG, AVR;ResectionCHD, HTNNoneNAWang Y et al. [14], 202373MNone8.4 × 6TVPResectionNone8NR in 15Actis Dato GM et al. [15], 202369FNone20 × 10ResectionNone6NAPhan TQ et al.,[16] 202317FDyspnea8.7 × 9.6ResectionNone3NR in 6Zhang RS et al.,[17] 202360FNone15 × 11Resection by cardiac catheterizationDM;HTN; TR, ischemic strokeNANAFang L et al. [18], 202251MDyspneaNATVR,Resection,TRNANARana Y et al.,[19] 202166MDyspnea17 × 13Resection,PFO closureHIV, DM, HTN, hyperlipidemia3NRKashiwagi Y et al.,[20] 202162FPalpitation23 × 17ResectionRBBB, PENANAKavalerchyk V et al. [21], 201874MChest pain,dyspnea10 × 8Conservative treatmentCHD-No change in 36Artunduaga M et al. [22], 20171FNone15 × 15TVP;ResectionNone6NARohani A et al. [23], 201764fChest pain9 × 6ResectionTRNANR in 6Gollol-Raju NSet al. [24], 201671MDyspnea11 × 9.4Resection by cardiac catheterizationNon-ischemic cardiomyopathy; HTN;NANR in 1Li W et al. [25], 201675MNone20 × 15TVP,ResectionCHD, HTN, ischemic stroke7NR in 6Choi KB t al [26], 201672MDyspnea,afebrile13 × 16TVP;ResectionNoneNANRShah RA et al. [27], 201565MDyspnea10 × 10 × 5ResectionTR, PE, PHNANR in 12Srivatsa SV et al.,[28] 201361FDyspnea13 × 9 × 11ResectionTR, PHNANR in 2Karimi M et al. [29], 20138MChest paindyspnea25 × 15TVR;ResectionTR, PENANRKarapanagiotidis GT et al. [30], 201281FDyspnea,Dizzy spells20 × 25TVP;ResectionTR7NR in 3Haron H et al. [31], 201268MAfebrile10 × 10MVR; TVP;ResectionDM;HTN; MI; TR6NR in 12Massarenti L et al. [32], 200950FNone16 × 17TVP;ResectionNone7NABoodhwani M et al. [33], 200738MDyspnea15 × 20TVP;ResectionNANANAMastroroberto P et al. [34], 200653MChest pain;dyspnea20 × 30CABG;ResectionCHD, PENANAGeorghiou GP al. [35], 200367FDyspnea25 × 16ResectionNoneNANR in 4Nishimura Y et al. [36], 199842FNone40 × 35TVP;ResectionTRNANR in 12Neerukonda SK et al. [37], 199175FDyspnea1.5 × 2.0/33 × 2.0 × 18TVP;ResectionPENANAWolfe JT 3rd et al. [38], 199175FNone27 × 27CABG;ResectionCerebral ischemic15Recurrence in 0.5Frumin H et al. [39], 198364FChest painsyncope15 × 15CABG;ResectionCHDNANACurrent study53FDyspnea10 × 9ResectionNone5NR in 12M,male;F,female;TVP,tricuspid valvuloplasty;MV, mitral valve;PVI, pulmonary vein isolation;AF,atrial fibrillation;NR, non-tumor recurrence; NA,not available; HTN, hypertension;CABG, coronary artery bypass grafting; CHD,coronary artery disease;AVR, aortic valve replacement;DM, diabetes mellitus;TR,tricuspid regurgitation;TVR,tricuspid valve replacement;HIV,human immunodeficiency virus;PFO,patent foramen ovale;PE,pulmonary embolism;RBBB,right bundle-branch block;PH:pulmonary arterial hypertension;MI,mitral insufficiency;MVR, mitral valve replacement Clinical Presentations of the Reported Cases and the Current Case TVP, MV repair, PVI, app ligation, Resection Chest pain; afebrile CABG, AVR; Resection TVP Resection Phan TQ et al., [16] 2023 Zhang RS et al., [17] 2023 DM; HTN; TR, ischemic stroke TVR, Resection, Rana Y et al., [19] 2021 Resection, PFO closure Kashiwagi Y et al., [20] 2021 Chest pain, dyspnea TVP; Resection Gollol-Raju NS et al. [24], 2016 TVP, Resection Dyspnea, afebrile TVP; Resection Srivatsa SV et al., [28] 2013 Chest pain dyspnea TVR; Resection Dyspnea, Dizzy spells TVP; Resection MVR; TVP; Resection DM; HTN; MI; TR TVP; Resection TVP; Resection Chest pain; dyspnea CABG; Resection TVP; Resection 1.5 × 2.0/ 33 × 2.0 × 18 TVP; Resection CABG; Resection Chest pain syncope CABG; Resection M,male;F,female;TVP,tricuspid valvuloplasty;MV, mitral valve;PVI, pulmonary vein isolation;AF,atrial fibrillation;NR, non-tumor recurrence; NA,not available; HTN, hypertension;CABG, coronary artery bypass grafting; CHD,coronary artery disease;AVR, aortic valve replacement;DM, diabetes mellitus;TR,tricuspid regurgitation;TVR,tricuspid valve replacement;HIV,human immunodeficiency virus;PFO,patent foramen ovale;PE,pulmonary embolism;RBBB,right bundle-branch block;PH:pulmonary arterial hypertension;MI,mitral insufficiency;MVR, mitral valve replacement Tumor size ranged from 5 × 6 mm to 40 × 35 mm, with no cases exceeding 40 mm. One case exhibited significant enlargement over a short period [37]. Tricuspid valve insufficiency was the most common comorbidity, and five cases were complicated by pulmonary embolism. Surgical resection, often combined with tricuspid valvuloplasty, was the primary treatment approach. Two cases were successfully treated via cardiac catheterization, a method that may warrant further consideration. One patient did not undergo surgery, and follow-up over three years showed no significant tumor progression [21]. The average hospital stay for surgical patients was 6.38 ± 3.09 days. There was one case of recurrence, but the patient died from a stroke 15 days postoperatively [21]. This raises the possibility that the tumor may not have been completely excised. There is no standardized treatment protocol for tricuspid valve PFE, and clinical experience remains limited [20]. The surgical indications is still controversial. Some authors advocate for surgical resection as the primary treatment unless contraindicated [51], while others recommend resection in all cases due to the potential risk of embolic complications, regardless of tumor size [15]. Conversely, some suggest a conservative approach, reserving surgery for cases with significant obstructive symptoms or a high embolic risk [11]. In patients with elevated surgical risk, antiplatelet therapy may be considered, though supporting relevant evidence remains limited [43]. By reviewing the literature, most of the patients were treated surgically and only one patient was treated conservatively for coronary artery disease (CHD) reason. The minimum diameter of surgical resection was 5*6 mm, so we suggest that patients with right-sided embolism and tricuspid valve PFE with a diameter greater than 5 mm should be treated surgically. Otherwise, conservative treatment should be performed. In our case, surgical resection was performed due to the tumor’s high mobility and risk of embolization. If the mass has a large pedicle or involves the valve, resection may require valve removal to prevent recurrence, followed by tricuspid valvuloplasty to restore normal blood flow. However, in our patient, the tumor had a small pedicle and was successfully excised without damaging the tricuspid valve leaflets, eliminating the need for valvuloplasty. Our team had considered a minimally invasive approach, such as aright mini-thoracotomy, However, considering the possibility of tricuspid valve repair and the risk of tumor detachment, we ultimately abandoned minimally invasive surgery. As tricuspid valve PFE is a benign tumor, prognosis following resection is generally excellent, with postoperative recurrence being rare [42]. A case of mitral valve PFE recurrence was reported nine years after initial resection of a tricuspid valve PFE [52], but no recent recurrence cases have been documented. Our patient was followed for one year with no signs of recurrence, clinical symptoms disappeared. Conclusion Tricuspid valve PFE is still a rare benign cardiac tumor. Echocardiography serves as a reliable diagnostic tool. By reviewing the literature, we suggest that for tricuspid valve PFE with right-sided embolism and with a diameter greater than 5 mm, early surgical resection should be considered to prevent serious complications such as embolization.